MAP2K7 and melanoma: One is a mechanistic study (3) that shows why combination therapy may be promising for BRAFV600E-positive melanomas and that it can work in xenograft mouse models, while the other, a clinical study (2), indicates improved outcome when patients are treated with a combination of both a BRAFV600E-specific inhibitor and a MEK inhibitor.